An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Trial Profile

An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs SG 2000 (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Spirogen
  • Most Recent Events

    • 20 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 20 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top